世界の動物向けOTC薬市場機会

Abstract

Overview:

Are you considering repositioning a product from the ethical to the OTC market? Gain insight into successful marketing strategies with this new report from Animal Pharm.

This report will be a particularly invaluable resource if you’re responsible for strategic planning, providing both a market overview and key issues for the decision making process.

This report will help you to:

• Examine the various market forces acting within the distribution of veterinary medicines
• Identify key drivers and the regulatory environment for different retail channels
• Review the leading companies in the OTC market
• Analyse the strengths and weaknesses of different strategies used for existing products

Executive Summary:

Traditionally sales of animal health products have been via a small number of different retail channels, limited by the regulatory classification of each specific product. Thus, products classified as being suitable for “over-the-counter” (OTC) sales have been widely available across all outlets (including supermarkets, pet superstores, garden centres, pet shops, pharmacies and veterinary clinics), while those restricted to being only available with a prescription have been limited to distribution through the so-called “ethical” channel of either a vet clinic or a pharmacy.

The different retail outlets represent separate marketing channels, and historically certain companies are predominantly active in particular channels. Reputations are built up over time and once forged these commercial relationships can provide a large degree of inertia within each channel of distribution. Companies are continually seeking new product opportunities. One potential opportunity for increasing sales volume would be to expand the number of pharmaceutical products available on the OTC market. Given the inherent difficulty and expense of developing new compounds, the simplest route is via the reclassification as OTC of pharmaceuticals formerly requiring prescriptions. This would then allow a much greater distribution across the range of retail outlets. For the manufacturer this offers the potential for increased volume and for the distributor, range expansion via new product launches. However, apart from the need to obtain regulatory approval, the switch into the general OTC market may conflict with existing ethical sales and cause manufacturers to have to rethink their relationship with those veterinarians who have previously supported a particular product. Nevertheless, for manufacturers with brands nearing the end of the product lifecycle, wider distribution via the OTC channel represents a potentially valuable method of extending profitable sales and generating revenue for re-investment into new compound development.

Table of Contents

CHAPTER 1 INTRODUCTION

• 1.1 Background
• 1.2 Managing the Product Life-cycle
• 1.3 Available OTC distribution channels
• 1.4 Distribution costs
• 1.5 Online pharm acies
• 1.6 OTC products: key market drivers

CHAPTER 2 ANIMAL HEALTH MARKETS

• 2.1 Global overview
• 2.2 EUROPE
  • 2.2.1 European pet market overview
  • 2.2.2 France
  • 2.2.3 Germany
  • 2.2.4 Spain
  • 2.2.5 UK Pet Market Size
  • 2.2.6 Other countries
• 2.3 NORTH AMERICA
  • 2.3.1 Canada
  • 2.3.2 United States
• 2.4 SOUTH AMERICA
  • 2.4.1 Argentina
  • 2.4.2 Brazil
• 2.5 FAR EAST/ASIA
  • 2.5.1 China
  • 2.5.2 India
  • 2.5.3 Japan
• 2.6 AUSTRALASIA
  • 2.6.1 Australia
  • 2.6.2 New Zealand

CHAPTER 3 LEGISLATION

• 3.1 Europe
  • 3.1.1 EMEA
  • 3.1.2 France
  • 3.1.3 Germany
  • 3.1.4 The Netherlands
  • 3.1.5 Spain
  • 3.1.6 United Kingdom
• 3.2 North America
  • 3.2.1 Canada
  • 3.2.2 United States
    • Pesticides
• 3.3 Australasia
  • 3.3.1 Australia
  • 3.3.2 New Zealand

CHAPTER 4 OTC ACTIVES

• 4.1 Overview
• 4.2 Ectoparasiticides
  • 4.2.1 Pyrethroids
  • 4.2.2 Organophosphorus compounds
  • 4.2.3 Carbamates and amidines
  • 4.2.4 Insect growth regulators
  • 4.2.5 Neonicotinoids
  • 4.2.6 Fipronil, selamectin and ivermectin
  • 4.2.7 Others (repellents)
• 4.3 Endoparasiticides

CHAPTER 5 CASE STUDIES

• 5.1 OTC spot-on ectoparasiticides
  • historical perspective
  • lessons to be learnt
• 5.2 OTC endoparasiticides
  • historical perspective
  • lessons to be learnt

CHAPTER 6 COMPANY PROFILES

• 6.1 Alfamed S.A.S.
• 6.2 Armitages Pet Products Limited
  • 6.2.1 Flea products
  • 6.2.2 Wormers
  • 6.2.3 Other animal health products
• 6.3 Battle, Hayward & Bower Ltd
• 6.4 Bayer Animal Health
• 6.5 Beaphar Nederland B.V.
• 6.6 Bio-Tech Solutions Ltd
• 6.7 Bob Martin (UK) Ltd
• 6.8 Central Garden & Pet Company
• 6.9 Chanelle Animal Health Ltd.,
• 6.10 Denes Natural Pet Care Ltd.
• 6.11 Dorwest Herbs Ltd
• 6.12 The Hartz Mountain Corporation
• 6.13 Intervet UK
• 6.14 Janssen Animal Health
• 6.15 Johnson' s Veterinary Products Ltd
  • Dog and cat products
  • Small animal products (for rabbits, guinea pigs, gerbils, hamsters, etc.)
  • Cage bird products
  • Pigeon products
• 6.16 Masterfoods (Complementary Petcare)
• 6.17 Merial
• 6.18 Novartis Animal Health I nc.
• 6.19 Petco Animal Supplies
• 6.20 Pets at Home
• 6.21 PetSmart
• 6.22 Schering -Ploug h Anim al Health
• 6.23 Sergeant' s Pet Care Products
  • Grocery/mass merchant ranges
  • Specialist pet store ranges
• 6.24 Seven Seas Pet and Anim al Heath Care
  • Seven Seas Overseas Distributors
• 6.25 Sinclair Anim al & Household Care
• 6.26 Virbac S.A.

LIST OF TABLES

• Table 2.1 World animal health market by year
• Table 2.2 World animal health market by region
• Table 2.3 World animal health market by species
• Table 2.4 World animal health market by category
• Table 2.5 French animal health market by species
• Table 2.6 French animal health market by category
• Table 2.7 Pet animal populations in France
• Table 2.8 German animal health market by category
• Table 2.9 German pet food market
• Table 2.10 German pet care product market
• Table 2.11 German pet population
• Table 2.12 Spanish animal health market by category
• Table 2.13 Spanish pet food market
• Table 2.14 Spanish animal health market by species
• Table 2.15 Spanish animal health market by region
• Table 2.16 UK sales of pet food and pet care products
• Table 2.17 UK animal medicine sales by species
• Table 2.18 Dog and cat populations in Scandinavian countries
• Table 2.19 Brazilian animal medicine sales by category
• Table 2.20 Brazilian animal market by species
• Table 2.21 Japanese pet food market by species
• Table 2.22 Japanese animal health market
• Table 2.23 Australian pet care market
• Table 2.24 Australian animal health market
• Table 2.25 Australian parasiticide market
• Table 6.1 Alfamed S.A.S. OTC Products authorized (AVM-GSL) in the UK
• Table 6.2 Armitage Bros. OTC Products authorized (AVM-GSL) in the UK
• Table 6.3 Battle, Haywood & Bower UK authorizations (AVM-GSL)
• Table 6.4 Bayer AG. Antiparasitic products authorized in the UK
• Table 6.5 Com parison of the classification of Bayer actives in UK and US
• Table 6.6 Beaphar OTC authorized (AVM-GSL) in the UK
• Table 6.7 Bio-Tech OTC Products authorized (AVM-GSL) in the UK
• Table 6.8 Bob Martin OTC Products authorized (AVM-GSL) in the UK
• Table 6.9 Central Garden & Pet Company sales ($ millions)
• Table 6.10 Central Garden & Pet Company Subsidiaries (pet supplies)
• Table 6.11 Zodiac range of OTC authorized (AVM-GSL) in the UK
• Table 6.12 Intervet pet wormers and flea collars authorized in the UK
• Table 6.13 Janssen AVM-GSL authorized products in UK
• Table 6.14 Johnsons Vet Products OTC authorized (AVM-GSL) in the UK
• Table 6.15 Masterfoods OTC range
• Table 6.16 Merial Sales Revenues ($ million)
• Table 6.17 Sales of Frontline and averm ectins by quarter ($ million)
• Table 6.18 Frontline range and UK classification
• Table 6.19 Novartis antiparasitics for com panion animals
• Table 6.20 Schering Ploug h Anim al Health AVM-GSL authorizations in UK
• Table 6.21 Sergeants older OTC authorized (AVM-GSL) in the UK
• Table 6.22 Seven Seas OTC authorized (AVM-GSL) in the UK
• Table 6.23 Sinclair OTC Products authorized (AVM-GSL) in the UK
• Table 6.24 Virbac, sales by region, 2005
• Table 6.25 Virbac UK authorized (AVM-GSL) products
• Table 6.26 Virbac Corporation, Revenue 2005
• Table 6.27 Canovel Range of OTC Products (AVM-GSL) in the UK

LIST OF FIGURES

• Figure 2.1 Number of UK households with each type of pet species
• Figure 2.2 US pet populations by species
• Figure 2.3 US pet care product market, 2005
• Figure 2.4 Australian pet population, 2005